Ixekizumab + Tirzepatide
Pre-clinicalRecruiting 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Psoriatic Arthritis (PsA)
Conditions
Psoriatic Arthritis (PsA), Obesity & Overweight
Trial Timeline
Feb 24, 2026 → May 1, 2030
NCT ID
NCT07443956About Ixekizumab + Tirzepatide
Ixekizumab + Tirzepatide is a pre-clinical stage product being developed by Eli Lilly for Psoriatic Arthritis (PsA). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07443956. Target conditions include Psoriatic Arthritis (PsA), Obesity & Overweight.
What happened to similar drugs?
10 of 20 similar drugs in Psoriatic Arthritis (PsA) were approved
Approved (10) Terminated (0) Active (10)
Hype Score Breakdown
Clinical
3
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07443956 | Pre-clinical | Recruiting |
| NCT06588283 | Phase 3 | Active |
| NCT06588296 | Phase 3 | Active |
Competing Products
20 competing products in Psoriatic Arthritis (PsA)